What smart money is saying about Illumina, Inc.
4 funds in our archive have pitched Illumina, Inc., most recently Argent Mid Cap Strategy in September 2026.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
15 lettersToo few moves on Illumina, Inc. yet for a clear signal
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 17 fund letters reported a position in Illumina, Inc., with 2 buys (opened or added) and 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 11 | 1 | 2 | 1 |
| Q2 2026 | 2 | 0 | 0 | 0 |
| Q1 2026 | 2 | 0 | 0 | 0 |
| Q3 2025 | 1 | 0 | 1 | 0 |
| Q2 2025 | 1 | 1 | 0 | 1 |
| Q1 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 17 positions · 5 moves
- New positionArgent Mid Cap StrategySeptember 2026
“Illumina, which we also initiated during the quarter, contributed significantly as well.”
Illumina, Inc. - September 2026
“Top contributors to performance included Illumina, Inc., IQVIA Holdings Inc., and SharkNinja, Inc. Illumina benefited from continued uptake for its DNA sequencing technology as well as a positive outlook for diagnostics from Grail, a company it was compelled to spin out but where they retain a significant equity stake.”
Illumina, Inc. - September 2026
“Portfolio Commentary The Large Cap Equity composite was up 1.19% in the quarter, net of fees, compared to a return of 2.30% for the S&P 500. Top contributors to performance included Illumina, Inc., IQVIA Holdings Inc., and SharkNinja, Inc. Illumina benefited from continued uptake for its DNA sequencing technology as well as a positive outlook for diagnostics from Grail, a company it was compelled to spin out but where they retain a significant equity stake.”
Illumina, Inc. - September 2026
“For Dexcom and Illumina , earlier weakness reflected genuine operational difficulties, so patience required evidence that execution was improving. Dexcom, whose continuous glucose monitors help people manage diabetes, has consistently delivered margin improvement and accelerating patient additions as it continues to expand the use of its technology across new patient populations. Illumina, a leader in DNA sequencing, has returned to stronger growth, raised its outlook and continued to increase adoption of NovaSeq X, its next-generation DNA sequencing platform.”
Illumina, Inc. - September 2026
“For Dexcom and Illumina , earlier weakness reflected genuine operational difficulties, so patience required evidence that execution was improving.”
Illumina, Inc. - September 2026
“We exited Intuit, Carrier Global, Lowe’s, American International Group, and Illumina, where either our conviction had moderated or much of the investment thesis had been realized.”
Illumina, Inc. - September 2026
“• Illumina is a leading provider of next-generation sequencing systems used in genetic research and increasingly in cancer diagnosis and treatment. Shares rose during the quarter on stronger-than-expected clinical growth, while Roche’s competitive product launch has been underwhelming, reducing a key risk to our investment thesis.”
Illumina, Inc. - September 2026
“• Illumina is a leading provider of next-generation sequencing systems used in genetic research and increasingly in cancer diagnosis and treatment. Shares rose during the quarter on stronger-than-expected clinical growth, while Roche’s competitive product launch has been underwhelming, reducing a key risk to our investment thesis.”
Illumina, Inc. - HoldsWCM Global Growth LimitedSeptember 2026
Listed in WCM Global Growth Limited’s reported holdings.
Illumina, Inc. - TrimmedSpyglass Growth StrategySeptember 2026
“During the third quarter, the positions that were most significantly trimmed were Snowflake, Illumina, and Medpace.”
Illumina, Inc. - HoldsBaron SMID Cap ETFSeptember 2026
“Life sciences tools & services finally got some wind in its sails as fundamentals appear to be on track for meaningful improvement. Standouts in this sub-industry included Tempus AI, Inc., a cancer diagnostics and AI driven data analytics company, which added 1.31%; Repligen Corporation, a provider of equipment used to manufacture biologic drugs, which added 0.75%; Illumina, Inc., the leading provider of gene sequencing equipment, which contributed 0.67%; and Stevanato Group S.p.A.”
Illumina, Inc. - June 2026
“Portfolio Commentary Hardman Johnston’s Large Cap Equity composite delivered a return of 9.5% in the second quarter and 10.1% for the first six months of 2026, both net of fees. These compared to 15.2% and 10.2% for the S&P 500 Index. In the quarter, performance was driven by gains in Illumina, Inc., SharkNinja, Inc., and Vertiv Holdings Co.”
Illumina, Inc. - June 2026
“• Biotechnology company Illumina is the leading producer of next- generation sequencing systems, which are used to sequence DNA for research and are increasingly important in cancer diagnosis and treatment.”
Illumina, Inc. - March 2026
“Edwards Lifesciences Corp. United States 2.7 Health Care Equipment & Supplies Illumina, Inc. United States 2.5 Life Sciences Tools & Services”
Illumina, Inc. - March 2026
“Portfolio Holdings Data as of March 31, 2026. Source: FactSet, Hardman Johnston Global Advisors LLC®. The data shown is of a representative portfolio for the Hardman Johnston Select Equity strategy and is for informational purposes only and is not indicative of future portfolio characteristics/returns. Actual results may vary for each client due to specific client guidelines and other factors. The representative portfolio was chosen as most representative of the Select Equity strategy. Future investments may or may not be profitable. C ountry We ig ht ( %) Indus try Communicat ion Serv ices 8.1 Alphabet Inc. United States 7.1 Interactive Media & Services Comcast Corp. United States 0.9 Diversified Telecommunication Services Versant Media Group, Inc. United States 0.1 Media Consumer Discret ionary 2.7 SharkNinja, Inc. United States 2.7 Household Durables Consumer St aples 0.8 Estee Lauder Companies Inc. United States 0.8 Personal Care Products Energy 1.9 Cameco Corporation Canada 1.9 Oil, Gas & Consumable Fuels Financials 9.7 Charles Schwab Corp United States 3.0 Capital Markets Marsh & McLennan Cos. Inc. United States 3.0 Insurance Mastercard Inc. United States 3.8 Financial Services H ealt h Care 17.9 AstraZeneca plc United Kingdom 3.5 Pharmaceuticals Becton, Dickinson & Co. United States 1.4 Health Care Equipment & Supplies Edwards Lifesciences Corp. United States 2.8 Health Care Equipment & Supplies Illumina, Inc. United States 2.0 Life Sciences Tools & Services”
Illumina, Inc. - September 2025
“ We added to Align Technology (ALGN) and Elevance Health (ELV) in Health Care and trimmed Illumina (ILMN).”
Illumina, Inc. - June 2025
“We also added to our position in the leading DNA sequencing platform, Illumina, Inc.”
Illumina, Inc.
Fund coverage · 4 theses
- Argent Mid Cap StrategySeptember 2026
Illumina is stabilizing and benefiting from clinical sequencing growth, recurring consumables, and a refocused strategy with improving profitability.
Read the full thesis - Baron Global Advantage FundJune 2025
Illumina, Inc. is a leading DNA sequencing platform with strong long-term growth potential despite recent pressures, driven by its competitive advantages in the expanding $40 billion clinical diagnostics market.
Read the full thesis - Diamond Hill Small Mid Cap FundMarch 2025
Illumina is a leader in genetic sequencing with an 80% market share, strong fundamentals, and promising long-term growth potential despite recent share price pressures.
Read the full thesis - Brown AdvisoryDecember 2024
Illumina is a leading U.S. life science and diagnostics company that has revolutionized gene sequencing, significantly reducing costs and driving growth in personalized medicine, while maintaining a dominant market share and high customer switching costs.
Read the full thesis
Read every full thesis on Illumina, Inc.
Read all 4 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→